These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9633686)

  • 41. Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease.
    Shim JS; Kim HG; Ju MS; Choi JG; Jeong SY; Oh MS
    J Ethnopharmacol; 2009 Nov; 126(2):361-5. PubMed ID: 19703534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
    Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
    Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors affecting levodopa effects in Parkinson's disease.
    Ogawa N
    Acta Med Okayama; 2000 Jun; 54(3):95-101. PubMed ID: 10925733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.
    Knaryan VH; Samantaray S; Le Gal C; Ray SK; Banik NL
    J Neurochem; 2011 Aug; 118(3):326-38. PubMed ID: 21615738
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.
    Engeln M; Fasano S; Ahmed SH; Cador M; Baekelandt V; Bezard E; Fernagut PO
    Ann Neurol; 2013 Jul; 74(1):140-4. PubMed ID: 23494678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does levodopa accelerate Parkinson's disease?
    Simuni T; Stern MB
    Drugs Aging; 1999 Jun; 14(6):399-408. PubMed ID: 10408739
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model.
    Inden M; Taira T; Kitamura Y; Yanagida T; Tsuchiya D; Takata K; Yanagisawa D; Nishimura K; Taniguchi T; Kiso Y; Yoshimoto K; Agatsuma T; Koide-Yoshida S; Iguchi-Ariga SM; Shimohama S; Ariga H
    Neurobiol Dis; 2006 Oct; 24(1):144-58. PubMed ID: 16860563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease.
    Cai XY; Kong XM; Fang Q; Ning P; Xu YJ; Zhang B; Xue SR
    Neurodegener Dis; 2012; 9(1):11-7. PubMed ID: 21876323
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease.
    Yokoyama H; Kuroiwa H; Yano R; Araki T
    Neurol Sci; 2008 Oct; 29(5):293-301. PubMed ID: 18941931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
    McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
    J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress.
    Nataraj J; Manivasagam T; Thenmozhi AJ; Essa MM
    Nutr Neurosci; 2016 Jul; 19(6):237-46. PubMed ID: 25730317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
    Melamed E
    J Neural Transm Suppl; 1995; 45():57-60. PubMed ID: 8748609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.
    Baluchnejadmojarad T; Eftekhari SM; Jamali-Raeufy N; Haghani S; Zeinali H; Roghani M
    Exp Gerontol; 2017 Dec; 100():70-76. PubMed ID: 29107062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of dopamine agonists in early Parkinson's disease.
    Watts RL
    Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
    Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
    Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.